Denosumab biosimilar by Sandoz Group for Humoral Hypercalcemia of Malignancy: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Humoral Hypercalcemia of Malignancy.

Source link
#Denosumab #biosimilar #Sandoz #Group #Humoral #Hypercalcemia #Malignancy #Likelihood #Approval